摘要
目的评价低分子肝素联合奥扎格雷钠治疗急性脑梗死的有效性及安全性。方法将96例符合诊断标准的急性脑梗死患者随机分成3组,每组32例,分别给予低分子肝素联合奥扎格雷钠(联合组)治疗,并与单纯应用低分子肝素(低分子肝素组)和单纯应用奥扎格雷钠(奥扎格雷钠组)治疗的患者进行临床疗效、治疗前后神经功能缺损程度评分(NDS)的比较。结果治疗后联合组显效率(75%)明显优于低分子肝素组(31.3%)及奥扎格雷钠组(34.4%),NDS减分程度与低分子肝素组及奥扎格雷钠组相比,差异均有统计学意义(P<0.05,P<0.01)。结论低分子肝素联合奥扎格雷钠治疗急性脑梗死疗效显著并且安全可靠。
Objective To evaluate the effectiveness and safety of Low-Molecular-Weight heparin in combination with unite Ozagrel sodium on treating patients of acute brain infarct.Methods 96 cases of acute cerebral infarction patients were randomly divided into three groups,32 cases each group.The patients were given Low-Molecular-Weight heparin in combination with Ozagrel sodium （union group）,and were given low molecular heparin （low molecular heparin group） and pure Ozagrel sodium （Ozagrel sodium group）respectively.Clinical curative effect,the nerve function damage degree grades （NDS） were compared before and after treatment.Results After the treatment,the efficiency of union group changed more obviously （75%） than those of low molecular heparin group （31.3%） and Ozagrel sodium group （34.4%）.Compared with low molecular heparin group and Ozagrel sodium group,there were obvious differences of NDS（P〈0.05,P〈0.01）.Conclusion It is effective and credible that Low-Molecular-Weight heparin in combination with Ozagrel sodium treats the patients of acute brain infarct.
出处
《实用药物与临床》
CAS
2009年第6期448-449,共2页
Practical Pharmacy and Clinical Remedies
关键词
脑梗死
低分子肝素
奥扎格雷钠
Acute brain infarct
Low-Molecular-Weight heparin
Ozagrel sodium
